Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas.

Furudate, Sadanori; Fujimura, Taku; Kambayashi, Yumi; Kakizaki, Aya; Hidaka, Takanori; Aiba, Setsuya

Furudate, Sadanori; Fujimura, Taku; Kambayashi, Yumi; Kakizaki, Aya; Hidaka, Takanori; Aiba, Setsuya.

Affiliation

Furudate S; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Fujimura T; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan tfujimura1@mac.com.
Kambayashi Y; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kakizaki A; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hidaka T; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Aiba S; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Anticancer Res ; 37(7): 3461-3471, 2017 07.

Article de En | MEDLINE | ID: mdl-28668835

Sujet(s)
Mots clés

Tumor-associated macrophages; imiquimod; melanoma; regulatory T cells; splenic CD11b+ cells

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links

Collection: 01-internacional Base de données: MEDLINE Sujet principal: Mélanome expérimental / Chimiokine CCL22 / Aminoquinoléines / Facteurs immunologiques / Macrophages Type d'étude: Prognostic_studies / Risk_factors_studies Limites: Animals Langue: En Journal: Anticancer Res Année: 2017 Type de document: Article Pays d'affiliation: Japon Pays de publication: Grèce

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links